Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of information regarding 44th Annual General Meeting of the Company30-08-2022
30-08-2022
Jubilant Pharmova Ltd - 530019 - USFDA Communication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a press release pertaining to receipt of Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for radiopharmaceuticals manufacturing facility of subsidiary company Jubilant Draximage Inc., at Montreal Canada. We request you to take the same on record.26-08-2022
Jubilant Pharmova Ltd - 530019 - Early Redemption Of 6% Senior Notes Due In 2024 By Jubilant Pharma Limited, Wholly-Owned Subsidiary Of The Company
Early Redemption of 6% Senior Notes Due in 2024 by Jubilant Pharma Limited, wholly-owned subsidiary of the Company19-08-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the transcript of Analyst and Investor Conference Call for Unaudited financial results for the quarter ended June 30, 2022 conducted after the meeting of Board of Directors held on Tuesday, August 2, 2022. This is for your information and records.08-08-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated August 2, 2022, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2022 published on August 3, 2022 in MINT (English) and HINDUSTAN (Hindi). We request you to take the same on record.05-08-2022
Results Earnings Call for Q1FY23 of Jubilant Pharmova
Conference Call with Jubilant Pharmova Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.02-08-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
we wish to inform that audio recording of Analyst and Investor Conference Call for Unaudited financial results for the quarter ended June 30, 2022 held on Tuesday, August 2, 2022, has been uploaded on the Company''s website and same is given in the attached letter.02-08-2022
Jubilant Pharmova Ltd - 530019 - Completion Of USFDA Audit Of Solid Dosage Manufacturing Facility At Roorkee Plant
Completion of USFDA Audit of solid dosage manufacturing facility at Roorkee plant02-08-2022
Jubilant Pharmova Ltd - 530019 - Grant Of Stock Options
JLL Employees Stock Option Plan 2018 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Nomination, Remuneration and Compensation Committee (the 'Committee') of the Company has, at its meeting held on Monday, August 1, 2022, has granted stock options as per the attached details.02-08-2022
Q1FY23 Quarterly Result Announced for Jubilant Pharmova Ltd.
Pharmaceuticals firm Jubilant Pharmova announced Q1FY23 Result : Revenue was at Rs 1,452 Crore vs. Rs 1,635 Crore in Q1'FY22 and Rs 1,528 Crore in Q4’FY22 Reported EBITDA at Rs 204 Crore versus Rs 379 Crore in Q1'FY22 and Rs 244 Crore in Q4’FY22 In Q1’FY23, we witnessed COVID-related deals of Rs 70 Crore vs. Rs 220 Crore in Q1’FY22 and Rs 11 Crore in Q4’FY22 In Q1’FY23, we witnessed nil sales of Remdesivir vs Rs 133 Crore in Q1’FY22 and Rs 4 Crore in Q4’FY22 Finance costs at Rs 40 Crore vs. Rs 35 Crore in Q1'FY22 and Rs 40 Crore in Q4’FY22 . Higher finance cost vs. Q1’FY22 was due to increase in interest rates PAT was at Rs 47 Crore as compared with Rs 161 Crore in Q1'FY22 and Rs 59 Crore in Q4’FY22 EPS is Rs 2.96 versus Rs 10.09 in Q1'FY22 and Rs 3.74 in Q4’FY22 Capital expenditure for the quarter was Rs 98 Crore Revenue at Rs 722 Crore vs. Rs 632 Crore in Q1'FY22 and Rs 695 Crore in Q4’FY22. Over 90% of the revenues are from the North America region EBITDA at Rs 117 Crore vs. Rs 75 Crore in Q1’FY22 and Rs 149 Crore in Q4’FY22 with a margin of 16.2% vs. 11.9% in Q1’FY22 and 21.5% in Q4’FY22 Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “During the quarter, the Company reported YoY improvement in sales in Specialty Pharmaceuticals and CRDMO, which was offset by CDMO Sterile Injectables and Generics segments In Specialty Pharmaceuticals, the Radiopharmaceuticals segment reported higher sales and profitability on account of recovery from COVID-19 impact, while Radiopharmacies business witnessed higher sales on account of recovery from pandemic and launch of new products. Our Allergy Business continues to perform strongly and witnessed healthy growth YoY. In the CDMO sterile injectables segment, revenue stood lower YoY as in Q1’FY22 the business realized higher revenue from COVID-19 related contracts as compared to this quarter. Generics segment’s performance was impacted by pricing pressure in the US market and Import Alert related challenges, which resulted in lower performance as compared to Q1’FY22. In CRDMO, while our Drug Discovery Services segment continued to report robust growth led by higher volumes and stable pricing, the CDMO-API segment reported lower revenue as the Nanjangud plant is undergoing asset replacement and plant upgradation, which contributed to lower volumes. We are glad to share that the API demerger has become effective with April 1, 2022 as the appointed date. This demerger will enable to create synergies between CRO & CDMO businesses and help in supporting our customers for their needs from early stage of research to commercialization of active ingredients, and will provide competitive edge to this business. We would like to inform that for better understanding of performance and outlook of our various businesses, the Company has reorganized the reporting segments from Q1’FY23 onwards and the details are covered in this quarter’s investor materials.” Result PDF02-08-2022